6-Mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia

Leukemia

Volumn 15, Issue 1, 2001, Pages 74-79

  Schmiegelow, K ^a   Bretton Meyer, U ^a  

^a Rigshospitalet   (Denmark)

Author keywords

6 Mercaptopurine; Acute lymphocytic leukemia; Bone marrow toxicity; Child; Methotrexate; Thioguanine nucleotides

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DNA; DRUG METABOLITE; FOLINIC ACID; HEMOGLOBIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PURINE; THIOGUANOSINE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG BIOAVAILABILITY; DRUG ERYTHROCYTE LEVEL; DRUG MEGADOSE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL; PURINE SYNTHESIS; THROMBOCYTE COUNT;

EID: 0035125916     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401986     Document Type: Article

References (33)

1. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia
2. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology
3. Cytotoxic mechanism of 6-thioguanine: hMutS-alfa, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine
4. The clinical pharmacology of 6-mercaptopurine
5. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
6. Methylation pharmacogenetics; catechol O-methyltransferase, thiopurine methyltransferase and histamine N-methyltransferase
7. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: A Pediatric Oncology Group pilot study
8. Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: Analysis by contemporary risk classifications
9. Childhood leukemias
10. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia - A logistic regression analysis
11. Physician compliance and relapse rates of acute lymphoblastic leukemia in children
12. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia
13. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
14. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine
15. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages
16. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Haematology and Oncology (NOPHO)
17. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells - Relation to thiopurine metabolism
18. Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6- thiouric acid in biological fluids by high-performance liquid chromatography
19. A rapid, radiochemical-ligand binding assay for methotrexate
20. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency
21. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Should dosage be guided by white blood cell counts?
22. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia
23. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
24. Clinical pharmacokinetics of commonly used anticancer drugs
25. Mechanism of action of methotrexate. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Erlich ascites tumor cells in vitro
26. Polyglutamation of methotrexate: Is methotrexate a prodrug?
27. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate
28. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia
29. Interrupted vs. continued maintenance therapy in childhood acute leukemia
30. Methotrexate and 6-mercaptopurine maintenance chemotherapy for childhood acute lymphoblastic leukemia: Dose adjustments by white cell counts or by pharmacokinetic parameters
31. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX)